학술논문

Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach.
Document Type
Journal Article
Source
Journal of Gastrointestinal Surgery. Jan2016, Vol. 20 Issue 1, p172-179. 8p.
Subject
*STOMACH cancer treatment
*ADJUVANT treatment of cancer
*CANCER chemotherapy
*CANCER radiotherapy
*GASTRECTOMY
*SURGICAL complications
*CANCER treatment
*ADENOCARCINOMA
*COMBINED modality therapy
*SURGICAL excision
*LYMPH node surgery
*RADIOTHERAPY
*STOMACH tumors
*RETROSPECTIVE studies
*TUMOR treatment
Language
ISSN
1091-255X
Abstract
Delayed recovery after gastrectomy may preclude the administration of adjuvant therapy in a significant percentage of patients who undergo elective gastrectomy as the initial therapy for gastric cancer. Clinicopathologic and treatment variables of 155 patients undergoing potentially curative gastrectomy for stages Ib-IIIc gastric adenocarcinoma from 2001 to 2014 were analyzed, and rates of receipt of chemotherapy and radiotherapy in patients treated with either a surgery-first approach (SURG) or neoadjuvant therapy followed by surgery followed by postoperative therapy (PERIOP) were compared. SURG patients (n = 93) were older and more likely to have distal tumors and to undergo distal gastrectomy and D1 lymphadenectomy than PERIOP patients (n = 62). The distribution of ASA scores was similar between groups. SURG patients were less likely than PERIOP patients to complete at least one cycle of chemotherapy (56 vs 100%, P = 0.001) and all recommended chemotherapy and radiation therapy (44 vs 66%, P = 0.013). These findings were consistent for SURG patients treated during different time periods throughout the study and for patients of poorer performance status. A significantly higher percentage of gastric cancer patients treated with perioperative chemotherapy receive some or all of the recommended components of multimodality therapy than patients treated with a surgery-first approach. [ABSTRACT FROM AUTHOR]